荆花胃康胶丸联合四联疗法在幽门螺杆菌 感染患者中的应用效果

Effect of Jinghua Weikang capsules combined with quadruple therapy on Helicobacter pylori infection

摘要:

目的 探讨荆花胃康胶丸联合四联疗法在幽门螺杆菌（Hp）感染患者中的应用效果。方法 684 例幽门螺杆菌感染的慢性胃炎患者按照分层随机法将患者随机分为A、B、C 及D 4 组，每组171 例。A 组治 疗方案：荆花胃康胶丸+ 奥硝唑胶囊+ 泮托拉唑+ 阿莫西林，10 d 为1 个疗程（1 ～ 10 d）。B 组治疗方案： 1 ～ 10 d 治疗方案同A 组，11 ～ 28 d 服用荆花胃康胶丸。C 组治疗方案：铝镁加合剂+ 奥硝唑胶囊+ 泮托 拉唑+ 阿莫西林，10 天为1 个疗程（1 ～ 10 d）。D 组治疗方案：1 ～ 10 d 治疗方案同C 组，11 ～ 28 d 服用荆 花胃康胶丸。比较4 组患者幽门螺杆菌根除率、治疗结束时与结束后4 周的症状缓解情况、不良反应发生 率。结果 数据分析结果显示，A、B、C、D 4 组患者幽门螺杆菌感染根治率分别为76.6%、80.0%、84.9% 和 93.5% ；4 组患者之间的幽门螺杆菌感染根治率比较差异有统计学意义（P <0.05）；A、B、C 3 组患者的幽门 螺杆菌感染根治率分别与D 组比较，差异有统计学意义（P <0.05）。意向性治疗分析结果显示，A、B、C、D 4 组患者幽门螺杆菌感染根治率为74.9%、79.5%、82.5% 和91.8% ；4 组患者之间的幽门螺杆菌感染根治率比 较差异有统计学意义（P <0.05）；A、B、C 3 组患者的幽门螺杆菌感染根治率分别与D 组比较，差异有统计 学意义（P <0.05）；4 组患者治疗前上腹胀、上腹痛、嗳气、纳差症状评分差异无统计学意义（P >0.05）；与 治疗前症状评分相比，治疗结束和治疗结束后4 周上腹胀、上腹痛、嗳气、纳差症状评分均得以改善；4 组 患者治疗结束和治疗结束后的纳差评分差异有统计学意义（P <0.05）；4 组患者不良反应发生率的比较差异 无统计学意义（P >0.05）。结论 荆花胃康胶丸联合四联疗法治疗幽门螺杆菌感染疗效明显优于含铝镁剂的四 联疗法。

Abstract:

Objective To investigate the effect of Jinghua Weikang capsules combined with quadruple therapy on Helicobacter pylori infection. Methods A total of 684 cases of chronic gastritis with Helicobacter pylori infection were randomly divided into a group A, a group B, a group C, and a group D according to stratified random method, with 171 cases in each group. The treatment plan for the group A was Jinghua Weikang capsules+Ornidazole capsules+ Pantoprazole+Amoxicillin, 10 days for a course of treatment (day 1 to day 10). The treatment plan for the group B included the same treatment plan as the group A for the first 10 days, and taking Jinghua Weikang capsules from day 11 to day 28. The treatment plan for the group C was aluminum magnesium additive+Ornidazole capsules+Pantoprazole+ Amoxicillin, 10 days for a course of treatment (day 1 to day 10). The treatment plan for the group D included the same treatment plan as the group C for the first 10 days, and taking Jinghua Weikang capsules from day 11 to day 28. The eradication rate of Helicobacter pylori, the remission of symptoms and the incidence of adverse reactions at the end of treatment and 4 weeks after completion of the treatment were compared among the 4 groups. Results Schema data analysis results showed that, the eradication rate of Helicobacter pylori infection in the groups A, B, C and D was respectively 76.6%, 80.0%, 84.9% and 93.5%; there were significant differences in the radical control rate of Helicobacter pylori infection among the 4 groups (P < 0.05), the radical control rate of Helicobacter pylori infection in the group D was significantly different from those in the groups A, B and C (P < 0.05). Intention-to-treat analysis showed that, the eradication rate of Helicobacter pylori infection in the groups A, B, C and D was 74.9%, 79.5%, 82.5% and 91.8% respectively; there were significant differences in the radical control rate of Helicobacter pylori infection among the 4 groups (P < 0.05), the radical control rate of Helicobacter pylori infection in the group D was significantly different from those in the groups A, B and C (P < 0.05). There were no significant differences in the score of upper abdominal distension, upper abdominal pain, belching or anorexia among the 4 groups before treatment (P > 0.05). Compared with the pre-treatment symptom scores, the scores of upper abdominal distension, upper abdominal pain, belching and anorexia at the end of treatment and 4 weeks after completion of the treatment were significantly improved; there were significant differences in the anorexia score among the 4 groups at the end of treatment and 4 weeks after completion of the treatment (P < 0.05). There were no significant differences in the incidences of adverse reactions among the 4 groups (P > 0.05). Conclusions Jinghua Weikang capsules combined with quadruple therapy for the treatment of Helicobacter pylori infection is superior to its combination with quadruple therapy containing aluminum magnesium additive.